Enas Aboelkheir Abdelaleem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Enas Aboelkheir Abdelaleem has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Rabab A. Mohamed
Clinical Pathology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
4 shared publications- Eman F. Mohamed
Rheumatology Unit, Internal Medicine Department, Faculty of Medicine (Girls), Al-Azhar University, Cairo 11651, Egypt
3 shared publications - Nevin Hammam
Assuit University
3 shared publications - Nora Yousry Elsaid
Cairo University, Cairo, Egypt
3 shared publications - Rawhya R. El Shereef
Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt
3 shared publications - Samar Tharwat
Rheumatology and Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 20 (1)
Systemic Sclerosis and Abortion: Determining Factors and Clinical Significance in a Multicenter Study
Objective: The aim of this work was to identify disease-related factors associated with a history of spontaneous abortion in adult female patients with systemic sclerosis (SSc), and to further analyze the distinguishing features of SSc patients with recurrent versus single abortion episodes. Materials and Methods: This multicenter case-control study was extracted from a nationwide SSc cohort of 1,080 patients. Ninety-one female adult SSc patients (8.4%) with a history of spontaneous abortion before 20 completed weeks of gestation were compared with 91 age-matched female SSc patients without a history of spontaneous abortion. Clinical characteristics, comorbidities, organ involvement, medications, and laboratory parameters were analyzed. Results: Patients with spontaneous abortion had significantly longer disease duration (6.4±4.7 vs . 4.6±4.2 years; p =0.007), a higher prevalence of comorbidities (29.7% vs . 15.4%; p =0.03), more frequent telangiectasia (28.6% vs . 12.1%; p =0.009) and a higher frequency of mycophenolate mofetil use (29.7% vs . 15.4%; p =0.03) compared with patients without a history of spontaneous abortion. Recurrent spontaneous abortion occurred in 30 patients (33.0%). Compared with those with a single spontaneous abortion, patients with recurrent spontaneous abortion had significantly higher frequencies of Raynaud’s phenomenon ( p p =0.047), hypo-/hyperpigmentation ( p =0.03), cardiovascular involvement ( p =0.046), anti-Scl-70 positivity ( p =0.01), double autoantibody positivity ( p =0.017), and higher serum triglyceride levels ( p =0.006). Discussion: Patients with SSc have a higher risk of spontaneous abortion than the general population; this risk is likely driven by decidual vasculopathy and fibrosis. Factors contributing to spontaneous abortion were variable in previous reports, with hypertension and long disease duration among the most contributing factors. Conclusion: In women with SSc, spontaneous abortion is associated with longer disease duration, telangiectasia, higher serum creatinine levels, the presence of comorbidities, and the use of MMF. Recurrent spontaneous abortion is associated with anti-Scl-70 positivity, double autoantibody positivity, and hypertriglyceridemia.
- 7 September 2026
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 20 (1)
Open AccessSystemic Sclerosis and Abortion: Determining Factors and Clinical Significance in a Multicenter Study
Objective: The aim of this work was to identify disease-related factors associated with a history of spontaneous abortion in adult female patients with systemic sclerosis (SSc), and to further analyze the distinguishing features of SSc patients with recurrent versus single abortion episodes. Materials and Methods: This multicenter case-control study was extracted from a nationwide SSc cohort of 1,080 patients. Ninety-one female adult SSc patients (8.4%) with a history of spontaneous abortion before 20 completed weeks of gestation were compared with 91 age-matched female SSc patients without a history of spontaneous abortion. Clinical characteristics, comorbidities, organ involvement, medications, and laboratory parameters were analyzed. Results: Patients with spontaneous abortion had significantly longer disease duration (6.4±4.7 vs . 4.6±4.2 years; p =0.007), a higher prevalence of comorbidities (29.7% vs . 15.4%; p =0.03), more frequent telangiectasia (28.6% vs . 12.1%; p =0.009) and a higher frequency of mycophenolate mofetil use (29.7% vs . 15.4%; p =0.03) compared with patients without a history of spontaneous abortion. Recurrent spontaneous abortion occurred in 30 patients (33.0%). Compared with those with a single spontaneous abortion, patients with recurrent spontaneous abortion had significantly higher frequencies of Raynaud’s phenomenon ( p p =0.047), hypo-/hyperpigmentation ( p =0.03), cardiovascular involvement ( p =0.046), anti-Scl-70 positivity ( p =0.01), double autoantibody positivity ( p =0.017), and higher serum triglyceride levels ( p =0.006). Discussion: Patients with SSc have a higher risk of spontaneous abortion than the general population; this risk is likely driven by decidual vasculopathy and fibrosis. Factors contributing to spontaneous abortion were variable in previous reports, with hypertension and long disease duration among the most contributing factors. Conclusion: In women with SSc, spontaneous abortion is associated with longer disease duration, telangiectasia, higher serum creatinine levels, the presence of comorbidities, and the use of MMF. Recurrent spontaneous abortion is associated with anti-Scl-70 positivity, double autoantibody positivity, and hypertriglyceridemia.
- Open Access
- 27 November 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 69
Serum level of interleukin-11 in patients with rheumatoid arthritis; relation to disease activity and interstitial lung disease
Background: Rheumatoid arthritis is a complex autoimmune disease characterized by local and systemic inflammation. The purpose of this study was to assess serum level of circulating interleukin-11 in rheumatoid arthritis cases and to estimate its correlation with clinical and laboratory parameters of rheumatoid arthritis disease, especially interstitial lung disease and disease activity. Methodology: This was a case-control study carried out on sixty rheumatoid arthritis patients who were divided into two groups: thirty rheumatoid arthritis patients without interstitial lung disease and thirty rheumatoid arthritis patients with interstitial lung disease. The patients were classified according to the criteria for rheumatoid arthritis and were recruited from the outpatient and inpatient department of Rheumatology and Rehabilitation between June 2023 to February 2024. Thirty healthy participants were also included as control. Results: There was a statistically significant higher level of interleukin-11 among rheumatoid arthritis patients, both with interstitial lung disease and non-interstitial lung disease, compared to healthy controls ( P -value less than 0.001). However, the difference between the interstitial lung disease and non-interstitial lung disease groups was statistically insignificant (p-value greater than 0.05). Similarly, the association between interstitial lung disease type and interleukin-11 level in the interstitial lung disease group was not significant ( P -value > 0.05). Interleukin-11 levels had a significant role in detecting rheumatoid arthritis (compared to controls) at a cut-off value of 32.7 pg/mL, with a sensitivity of 96.67% and a specificity of 60%, a positive predictive value of 82.4%, and a negative predictive value of 81.8%. Conclusion: Interleukin-11 is highly elevated in both rheumatoid arthritis without interstitial lung disease and rheumatoid arthritis with interstitial lung disease but did not differentiate between them. This suggests that interleukin-11 is involved in the inflammatory process of both articular and extra-articular manifestations. However, in the absence of a correlation between the disease activity score for the twenty-eight-Joints and interleukin-11, further research is needed to understand its role in etiopathogenesis.
- 27 November 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 69
Open AccessSerum level of interleukin-11 in patients with rheumatoid arthritis; relation to disease activity and interstitial lung disease
Background: Rheumatoid arthritis is a complex autoimmune disease characterized by local and systemic inflammation. The purpose of this study was to assess serum level of circulating interleukin-11 in rheumatoid arthritis cases and to estimate its correlation with clinical and laboratory parameters of rheumatoid arthritis disease, especially interstitial lung disease and disease activity. Methodology: This was a case-control study carried out on sixty rheumatoid arthritis patients who were divided into two groups: thirty rheumatoid arthritis patients without interstitial lung disease and thirty rheumatoid arthritis patients with interstitial lung disease. The patients were classified according to the criteria for rheumatoid arthritis and were recruited from the outpatient and inpatient department of Rheumatology and Rehabilitation between June 2023 to February 2024. Thirty healthy participants were also included as control. Results: There was a statistically significant higher level of interleukin-11 among rheumatoid arthritis patients, both with interstitial lung disease and non-interstitial lung disease, compared to healthy controls ( P -value less than 0.001). However, the difference between the interstitial lung disease and non-interstitial lung disease groups was statistically insignificant (p-value greater than 0.05). Similarly, the association between interstitial lung disease type and interleukin-11 level in the interstitial lung disease group was not significant ( P -value > 0.05). Interleukin-11 levels had a significant role in detecting rheumatoid arthritis (compared to controls) at a cut-off value of 32.7 pg/mL, with a sensitivity of 96.67% and a specificity of 60%, a positive predictive value of 82.4%, and a negative predictive value of 81.8%. Conclusion: Interleukin-11 is highly elevated in both rheumatoid arthritis without interstitial lung disease and rheumatoid arthritis with interstitial lung disease but did not differentiate between them. This suggests that interleukin-11 is involved in the inflammatory process of both articular and extra-articular manifestations. However, in the absence of a correlation between the disease activity score for the twenty-eight-Joints and interleukin-11, further research is needed to understand its role in etiopathogenesis.
- Open Access
- 8 January 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 667-676
Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
- 8 January 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 667-676
Open AccessRheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.
- 16 April 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
- 16 April 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 989-998
Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
- Open Access
- 1 April 2022
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 44 (2) , 139-143
Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
- 1 April 2022
- Published by Elsevier in The Egyptian Rheumatologist
- Vol. 44 (2) , 139-143
Open AccessInterleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
- Open Access
- 16 April 2021
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 48 (1) , 1-7
Serum level of Adrenomedullin in patients with primary knee osteoarthritis; relation to disease severity
Background: Adrenomedullin (AM) is a peptide which was suggested to be involved in the pathogenesis of osteoarthritis through its anti-inflammatory and anti-apoptotic effect. AM was found to be elevated in some inflammatory rheumatic diseases as rheumatoid arthritis and ankylosing spondylitis. The current study was performed to measure serum Adrenomodullin (AM) concentrations in patients with primary knee osteoarthritis (KOA) and to assess association with severity of the disease. The study was performed on 50 patients with primary KOA diagnosed according to American College of Rheumatology (ACR) Revised Criteria for Early Diagnosis of Knee Osteoarthritis and 20 age- and sex-matched controls with no clinical features of KOA. The Kellgren and Lawrence (KL) classification was used to evaluate the disease severity of knee OA. Disease activity was assessed by The Western Ontario and McMaster Universities Arthritis Index (WOMAC). Blood samples had been collected from patients with OA and controls for assessing Adrenomodullin in patients’ sera by ELISA. Results: There were a significant increase in serum Adrenomedullin concentrations in KOA patients compared to controls (10.64 ±19.2 ng/ml vs. 1.39 ±1.6 ng/ml in cases and controls respectively) (p value = 0.036). There was positive significant correlation of serum Adrenomedullin levels with KL grades (r=0.608, p value 6 have significantly higher serum Adrenomedullin levels than OA patients with VAS Score 0.05). Conclusion: This study concluded that serum Adrenomedullin (AM) level is elevated in patients with KOA and is positively correlated with the severity of disease.
- 16 April 2021
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 48 (1) , 1-7
Open AccessSerum level of Adrenomedullin in patients with primary knee osteoarthritis; relation to disease severity
Background: Adrenomedullin (AM) is a peptide which was suggested to be involved in the pathogenesis of osteoarthritis through its anti-inflammatory and anti-apoptotic effect. AM was found to be elevated in some inflammatory rheumatic diseases as rheumatoid arthritis and ankylosing spondylitis. The current study was performed to measure serum Adrenomodullin (AM) concentrations in patients with primary knee osteoarthritis (KOA) and to assess association with severity of the disease. The study was performed on 50 patients with primary KOA diagnosed according to American College of Rheumatology (ACR) Revised Criteria for Early Diagnosis of Knee Osteoarthritis and 20 age- and sex-matched controls with no clinical features of KOA. The Kellgren and Lawrence (KL) classification was used to evaluate the disease severity of knee OA. Disease activity was assessed by The Western Ontario and McMaster Universities Arthritis Index (WOMAC). Blood samples had been collected from patients with OA and controls for assessing Adrenomodullin in patients’ sera by ELISA. Results: There were a significant increase in serum Adrenomedullin concentrations in KOA patients compared to controls (10.64 ±19.2 ng/ml vs. 1.39 ±1.6 ng/ml in cases and controls respectively) (p value = 0.036). There was positive significant correlation of serum Adrenomedullin levels with KL grades (r=0.608, p value 6 have significantly higher serum Adrenomedullin levels than OA patients with VAS Score 0.05). Conclusion: This study concluded that serum Adrenomedullin (AM) level is elevated in patients with KOA and is positively correlated with the severity of disease.
- Open Access
- 5 March 2021
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 48 (1) , 1-8
The role of Dickkopf-1 as a biomarker in systemic lupus erythematosus and active lupus nephritis
Background: Systemic lupus erythematosus (SLE) is a chronic disease which is mainly attributed to autoantibodies, cytokines, and immune complex deposition. Studies have demonstrated that cytokines and autoantibodies were strongly associated with renal diseases and can be used for the prediction of patients with lupus nephritis (LN). However, antibodies to dsDNA and the reduction of complements were also detected in non-LN patients as well as clinically non-active SLE patients. The current study was performed to detect the role of serum DKK-1 as a biomarker for the identification of SLE patients and patients with LN and its relation to disease activity and severity. The study was conducted on fifty clinically diagnosed SLE patients who were diagnosed according to Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE, in addition to thirty healthy control volunteers matched for age and sex. Assessment of SLE disease activity was done using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Assessment of SLE disease severity was done using the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage index. Serum levels of DKK-1 were measured for all participants by ELISA using commercially available kits. Results: DKK-1 serum levels were significantly higher among active lupus nephritis cases as compared with SLE cases with no LN and with healthy controls (9197.60 μg/uL ± 2939.2 μg/uL vs. 6405.15 μg/uL ± 2018.91 μg/uL vs. 2790.33 μg/uL ± 833.49 μg/uL) respectively (p-values < 0.001). DKK-1 concentration was significantly higher among SLE patients with positive as compared with negative anti-double-stranded DNA (dsDNA) antibodies (p-value < 0.001). According to receiver operating characteristic (ROC) curve analysis, serum DKK-1 level diagnosed the SLE at a statistically significant level with a 98% sensitivity and 70% specificity and serum DKK-1 level also diagnosed active lupus nephritis at a 90% sensitivity and 63% specificity. Conclusion: DKK-1 could diagnose SLE and lupus nephritis with high sensitivity and specificity. Serum DKK-1 is a reliable biomarker for the identification of SLE and patients with LN and could be used as a key molecule for the diagnosis of SLE and as a prognostic indicator of LN.
- 5 March 2021
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 48 (1) , 1-8
Open AccessThe role of Dickkopf-1 as a biomarker in systemic lupus erythematosus and active lupus nephritis
Background: Systemic lupus erythematosus (SLE) is a chronic disease which is mainly attributed to autoantibodies, cytokines, and immune complex deposition. Studies have demonstrated that cytokines and autoantibodies were strongly associated with renal diseases and can be used for the prediction of patients with lupus nephritis (LN). However, antibodies to dsDNA and the reduction of complements were also detected in non-LN patients as well as clinically non-active SLE patients. The current study was performed to detect the role of serum DKK-1 as a biomarker for the identification of SLE patients and patients with LN and its relation to disease activity and severity. The study was conducted on fifty clinically diagnosed SLE patients who were diagnosed according to Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE, in addition to thirty healthy control volunteers matched for age and sex. Assessment of SLE disease activity was done using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Assessment of SLE disease severity was done using the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage index. Serum levels of DKK-1 were measured for all participants by ELISA using commercially available kits. Results: DKK-1 serum levels were significantly higher among active lupus nephritis cases as compared with SLE cases with no LN and with healthy controls (9197.60 μg/uL ± 2939.2 μg/uL vs. 6405.15 μg/uL ± 2018.91 μg/uL vs. 2790.33 μg/uL ± 833.49 μg/uL) respectively (p-values < 0.001). DKK-1 concentration was significantly higher among SLE patients with positive as compared with negative anti-double-stranded DNA (dsDNA) antibodies (p-value < 0.001). According to receiver operating characteristic (ROC) curve analysis, serum DKK-1 level diagnosed the SLE at a statistically significant level with a 98% sensitivity and 70% specificity and serum DKK-1 level also diagnosed active lupus nephritis at a 90% sensitivity and 63% specificity. Conclusion: DKK-1 could diagnose SLE and lupus nephritis with high sensitivity and specificity. Serum DKK-1 is a reliable biomarker for the identification of SLE and patients with LN and could be used as a key molecule for the diagnosis of SLE and as a prognostic indicator of LN.
- Open Access
- 17 February 2021
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 48 (1) , 1-7
Functional disability and health-related quality of life in juvenile idiopathic arthritis children from Beni-Suef
Background: Juvenile idiopathic arthritis (JIA) is a common childhood disease which causes significant impairment in quality of life. The aim of the study is to assess the health-related quality of life and its relation to functional disability in JIA patients. Child health assessment questionnaire (CHAQ) and pediatrics quality of life 4 generic core questionnaire (PedsQL) were used to evaluate functional disability and health-related quality of life. Results: CHAQ (VAS) of JIA patients ranged from 0 to 9 with a mean of 3.64 ± 2.9 (SD), and of controls ranged from 0 to 4 with a mean of 1.32 ± 1.3 (SD) with a statistically significant difference and a p value of 0.001. CHAQ-disability index (DI) of the cases ranged from 0 to 3 with a mean of 1.06 ± 0.9 (SD) and of controls was consistent = 0. Pediatric quality of life (PedsQL) among cases ranged from 26.08 to 91.3 with a mean of 67.95 ± 19.2 (SD) and among controls ranged from 78.27 to 100 with a mean of 90.73 ± 7.7 (SD) showing statistically significant difference with a p value < 0.001. Childhood health assessment questionnaire (CHAQ) scores were significantly higher among studied females with JIA as compared with males. The mean CHAQ-DI scores were 4.56 ± 2.7 vs. 1.29 ± 2.6 in females and males respectively with a significant p value of 0.002. The mean CHAQ-(VAS) scores were 1.38 ± 0.8 vs. 0.23 ± 0.3 in females and males respectively with a significant p value of 0.016. Pediatric quality of life (PedsQL) scores were significantly higher among studied males with JIA as compared with studied females. The childhood health assessment questionnaire (CHAQ) was negatively correlated with all (physical, emotional, social, and school) items of the pediatric quality of life (PedsQL) (p < 0.001). Conclusion: We found a significant impairment in the functional ability and health-related quality of life in patients with JIA compared to healthy children, with more impairment in females than males. CHAQ was negatively correlated with all items of PedsQL.
- 17 February 2021
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 48 (1) , 1-7
Open AccessFunctional disability and health-related quality of life in juvenile idiopathic arthritis children from Beni-Suef
Background: Juvenile idiopathic arthritis (JIA) is a common childhood disease which causes significant impairment in quality of life. The aim of the study is to assess the health-related quality of life and its relation to functional disability in JIA patients. Child health assessment questionnaire (CHAQ) and pediatrics quality of life 4 generic core questionnaire (PedsQL) were used to evaluate functional disability and health-related quality of life. Results: CHAQ (VAS) of JIA patients ranged from 0 to 9 with a mean of 3.64 ± 2.9 (SD), and of controls ranged from 0 to 4 with a mean of 1.32 ± 1.3 (SD) with a statistically significant difference and a p value of 0.001. CHAQ-disability index (DI) of the cases ranged from 0 to 3 with a mean of 1.06 ± 0.9 (SD) and of controls was consistent = 0. Pediatric quality of life (PedsQL) among cases ranged from 26.08 to 91.3 with a mean of 67.95 ± 19.2 (SD) and among controls ranged from 78.27 to 100 with a mean of 90.73 ± 7.7 (SD) showing statistically significant difference with a p value < 0.001. Childhood health assessment questionnaire (CHAQ) scores were significantly higher among studied females with JIA as compared with males. The mean CHAQ-DI scores were 4.56 ± 2.7 vs. 1.29 ± 2.6 in females and males respectively with a significant p value of 0.002. The mean CHAQ-(VAS) scores were 1.38 ± 0.8 vs. 0.23 ± 0.3 in females and males respectively with a significant p value of 0.016. Pediatric quality of life (PedsQL) scores were significantly higher among studied males with JIA as compared with studied females. The childhood health assessment questionnaire (CHAQ) was negatively correlated with all (physical, emotional, social, and school) items of the pediatric quality of life (PedsQL) (p < 0.001). Conclusion: We found a significant impairment in the functional ability and health-related quality of life in patients with JIA compared to healthy children, with more impairment in females than males. CHAQ was negatively correlated with all items of PedsQL.
- Open Access
- 30 September 2019
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 44 (3) , 277-284
Tumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity
Aim of the study: The present case control study was conducted to assess the association of LTA 252 A>G, TNF-α 308 G>A, and TNF-α 1031 T>C gene polymorphisms with rheumatoid arthritis (RA), and their involvement in disease activity and severity. Material and methods: A total of 70 Egyptians, including 35 RA patients and 35 healthy control individuals, were included in the study. The RA patients comprised 34 females and one male. Cases with RA were diagnosed by a rheumatologist and fulfilled the 2010 ACR/EULAR criteria. Modified disease activity score (DAS28) was used to assess disease activity. Van Der Heijde-modified Sharp score (vdHSS) was used to assess radiological changes for assessment of disease severity. PCR-RFLP was used to detect the association of LTA 252 A>G, TNF-α 308 G>A, and TNF-α 1031 T>C gene polymorphisms with RA. Results: TNF-α 308 G allele and TNF-α 308 GG genotype were significantly higher in RA patients compared to healthy control subjects (p = 0.04 and p = 0.001, respectively). TNF-α 308 G allele and GG genotype were significantly higher in the RA non-remission group compared to the remission group (p = 0.008, p < 0.001). Patients with the TNF-α 308 AG genotype had higher mean of Sharp score compared to the patients with the GG and AA genotypes (p = 0.007). There was no significant association between LTA 252 A>G and TNF-α 1031 T>C gene polymorphisms and RA. Conclusions: Our results suggest that TNF-α 308 G/A gene polymorphism is genetically associated with RA and involved in disease activity and severity in Egyptian patients.
- 30 September 2019
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 44 (3) , 277-284
Open AccessTumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity
Aim of the study: The present case control study was conducted to assess the association of LTA 252 A>G, TNF-α 308 G>A, and TNF-α 1031 T>C gene polymorphisms with rheumatoid arthritis (RA), and their involvement in disease activity and severity. Material and methods: A total of 70 Egyptians, including 35 RA patients and 35 healthy control individuals, were included in the study. The RA patients comprised 34 females and one male. Cases with RA were diagnosed by a rheumatologist and fulfilled the 2010 ACR/EULAR criteria. Modified disease activity score (DAS28) was used to assess disease activity. Van Der Heijde-modified Sharp score (vdHSS) was used to assess radiological changes for assessment of disease severity. PCR-RFLP was used to detect the association of LTA 252 A>G, TNF-α 308 G>A, and TNF-α 1031 T>C gene polymorphisms with RA. Results: TNF-α 308 G allele and TNF-α 308 GG genotype were significantly higher in RA patients compared to healthy control subjects (p = 0.04 and p = 0.001, respectively). TNF-α 308 G allele and GG genotype were significantly higher in the RA non-remission group compared to the remission group (p = 0.008, p < 0.001). Patients with the TNF-α 308 AG genotype had higher mean of Sharp score compared to the patients with the GG and AA genotypes (p = 0.007). There was no significant association between LTA 252 A>G and TNF-α 1031 T>C gene polymorphisms and RA. Conclusions: Our results suggest that TNF-α 308 G/A gene polymorphism is genetically associated with RA and involved in disease activity and severity in Egyptian patients.
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 4 (2) , 98-103
Genetic influence of growth and differentiation factor 5 gene polymorphism (+104T/C) on the development of knee osteoarthritis and its association with disease severity
Objective: The growth and differentiation factor 5 (GDF5) gene is recognized for its role in the development, repair, and maintenance of cartilage and bone. The present case-control study was conducted to detect the genetic association between GDF5 (+104T/C) single-nucleotide polymorphism (SNP) and primary knee osteoarthritis (KOA), as well as the possible association of SNP with the severity of KOA. Material and Methods: The study included 50 patients with primary KOA and 50 healthy control subjects. The severity of the disease was assessed by using the Kellgren-Laurence (K-L) grading system and aided by the Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) score, visual analog scale (VAS) score, and tenderness score. The genetic association of the SNP with primary KOA was assessed by means of the TaqMan® allelic discrimination technique. Results: The radiological assessment of patients according to the K-L grading system revealed a statistically significant association between the wild-type (TT) genotype and disease severity in both the right and left knees (p=0.049). The frequency distribution of patients with VAS score ≤6 was significantly higher in patients carrying the TT genotype (p=0.005) as compared to the CT and CC genotypes. The mean WOMAC score was significantly higher in patients carrying the TT genotype as compared to patients carrying the CC and CT genotypes (p=0.017). No statistically significant association was detected on comparing the frequency distribution of allele and genotype frequencies of the SNP in patients and healthy controls. Conclusion: The results of the current study revealed a possible genetic association between GDF5 (+104T/C) SNP and the severity of KOA, which might be of benefit for the detection of patients with a high risk for disease progression. The present study did not detect an association between the SNP and development of KOA.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 4 (2) , 98-103
Open AccessGenetic influence of growth and differentiation factor 5 gene polymorphism (+104T/C) on the development of knee osteoarthritis and its association with disease severity
Objective: The growth and differentiation factor 5 (GDF5) gene is recognized for its role in the development, repair, and maintenance of cartilage and bone. The present case-control study was conducted to detect the genetic association between GDF5 (+104T/C) single-nucleotide polymorphism (SNP) and primary knee osteoarthritis (KOA), as well as the possible association of SNP with the severity of KOA. Material and Methods: The study included 50 patients with primary KOA and 50 healthy control subjects. The severity of the disease was assessed by using the Kellgren-Laurence (K-L) grading system and aided by the Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) score, visual analog scale (VAS) score, and tenderness score. The genetic association of the SNP with primary KOA was assessed by means of the TaqMan® allelic discrimination technique. Results: The radiological assessment of patients according to the K-L grading system revealed a statistically significant association between the wild-type (TT) genotype and disease severity in both the right and left knees (p=0.049). The frequency distribution of patients with VAS score ≤6 was significantly higher in patients carrying the TT genotype (p=0.005) as compared to the CT and CC genotypes. The mean WOMAC score was significantly higher in patients carrying the TT genotype as compared to patients carrying the CC and CT genotypes (p=0.017). No statistically significant association was detected on comparing the frequency distribution of allele and genotype frequencies of the SNP in patients and healthy controls. Conclusion: The results of the current study revealed a possible genetic association between GDF5 (+104T/C) SNP and the severity of KOA, which might be of benefit for the detection of patients with a high risk for disease progression. The present study did not detect an association between the SNP and development of KOA.